Covered recipient · General Payments record
GRAHAM HENRY ERLACHER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,056.70
- Reported across 67 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $331.64 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $86.08 | 3 |
| Novo Nordisk AS | $48.40 | 3 |
| Lilly USA, LLC | $35.28 | 2 |
| PFIZER INC. | $33.03 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.59 | 1 |
| Alexion Pharmaceuticals, Inc. | $22.10 | 1 |
| GlaxoSmithKline, LLC. | $20.68 | 1 |
| Kyowa Kirin, Inc. | $19.39 | 1 |
| Amgen Inc. | $13.78 | 1 |
| Acerta Pharma LLC | $13.74 | 1 |
| Sonex Health, Inc. | $13.57 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $33.29 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103696860 | CMS |
| ABBVIE INC. | $32.98 | 02/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103696862 | CMS |
| ABBVIE INC. | $19.81 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103696864 | CMS |
| Alexion Pharmaceuticals, Inc. | $22.10 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1093959770 | CMS |
| Amgen Inc. | $13.78 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111570869 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.74 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104326102 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $25.59 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117834924 | CMS |
| GlaxoSmithKline, LLC. | $20.68 | 03/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116319398 | CMS |
| Kyowa Kirin, Inc. | $19.39 | 03/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127030789 | CMS |
| Lilly USA, LLC | $15.02 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135013799 | CMS |
| Lilly USA, LLC | $20.26 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135013801 | CMS |
| Novo Nordisk Inc | $14.29 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096826225 | CMS |
| Novo Nordisk Inc | $17.86 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096794858 | CMS |
| Novo Nordisk Inc | $16.25 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097062697 | CMS |
| PFIZER INC. | $13.84 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132043510 | CMS |
| PFIZER INC. | $19.19 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132048064 | CMS |
| Sonex Health, Inc. | $13.57 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134568890 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.